Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

NCT02508532 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.

NCT NCT02508532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02508532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Lead sponsor
Blueprint Medicines Corporation
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2015
Completion date
June 3, 2021
Enrollment
250 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumors (gist), other relapsed or refractory solid tumors